Dysplasia of human prostate CD133hi sub-population in NOD-SCIDS is blocked by c-myc anti-sense

Prostate

Volumn 69, Issue 7, 2009, Pages 689-698

  Goodyear, S M ^a   Amatangelo, M D ^a   Stearns, M E ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b MS 435 ^*  (United States)

Author keywords

c myc; CD133; Dysplasia; Intermediary basal cells; NOD SCIDS

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD133 ANTIGEN; CD24 ANTIGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; MYC PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; COMPLEMENTARY DNA; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MYC PROTEIN, HUMAN; PEPTIDE; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENIC ACTIVITY; CELL CULTURE; CELL GROWTH; CELL IMMORTALIZATION; CELL POPULATION; CELL STRAIN; CONTROLLED STUDY; DYSPLASIA; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROSTASPHERE; PROSTATE DISEASE; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; KARYOTYPING; MIDDLE AGED; MOUSE MUTANT; PATHOLOGY; PROSTATE TUMOR; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; DNA, ANTISENSE; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; KARYOTYPING; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; PEPTIDES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TELOMERASE; TRANSFECTION;

EID: 65449145202     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20918     Document Type: Article

References (37)

1. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28:98-106.
2. Isaacs JT. Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model. In: Rogers CH, Coffey DS, Cunha G, Grayhack JT, Hinman F, Horton R. editors. Benign Prostate hyperplasia, Vol.II. Bethesda, MD: NIH Publication; 1987. pp. 85-94.
3. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia Prostate Suppl 1989;2:33-50.
4. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994;24:114-118. (Pubitemid 24109590)
5. Bonkhoff H, Stein U, Aumuller G, Remberger K. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996;29:261-267. (Pubitemid 26365292)
6. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma and postmitotic cells. Hum Pathol 1995;26:167-170.
7. De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998;160(6 Pt 2):2381-2392.
8. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: Expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998;153:911-919.
9. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancies. J Urol 1995;153:1085-1096.
10. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993;143:390-400. (Pubitemid 24058194)
11. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers drug resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
12. Bonkhoff H. Role of the basal cells in premalignant changes of the human prostate: A stem cell concept for the development of prostate cancer. Eur Urol 1996;30:201-205.
13. Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Sem Canc Biol 1997;8:21-27.
14. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R. Tissue expression of neu differentiation factor/ heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997;3:21-30. (Pubitemid 27161030)
15. Sommerfield HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: A prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-223.
16. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev 1999;17:391-399. (Pubitemid 29331789)
17. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status. Prostate (Suppl) 1998;8:18-22.
18. Abrahamsson PA. Neuroendocrine differentiation and hormone- refractory prostate cancer. Prostate (Suppl) 1996;6:3-8. (Pubitemid 26112281)
19. Collins AT, Habib FK, Maitland NJ, Neal DE, Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001;114(Pt 21):3865-3872.
20. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70(1 suppl):254-268.
21. Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998;51:585-589. (Pubitemid 28186211)
22. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate; simultaneous demonstration of cell-specific epithelial marker. Hum Pathol 1994;25:42-46. (Pubitemid 24051823)
23. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-10951. (Pubitemid 41713363)
24. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG. Highly purified CD44+prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25(12):1696-1708.
25. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57(3):524-531. (Pubitemid 27081674)
26. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008;21:1156-1167.
27. Felsher D, Bishop JM, Reversible Tumorigenesis by MYC in Hematopoietic Lineages. Mol Cell 1999;4(2):199-207. (Pubitemid 29456888)
28. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431(7012):1112-1117. (Pubitemid 39472236)
29. Waikel RL, Kawachi Y, Waikel PA, Wang XJ, Roop DR. Deregulated expression of c-Myc depletes epidermal stem cells. Nat Genet 2001;28:165-168. (Pubitemid 32538063)
30. Wilson A, Murphy M, Oskarsson T, Kaloulis K, Bettes M, Oser G, Pasche A, MacDonald HR, Trumpp A. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004;18:2747-2763. (Pubitemid 39507768)
31. Arnold I, Watt FM c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 2001;11(8):558-568. (Pubitemid 32324758)
32. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67(7):3153-3161. (Pubitemid 46724852)
33. Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 2003;100:3983-3988. (Pubitemid 36418143)
34. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117(Pt 16):3539-3545. (Pubitemid 39206394)
35. Okita KI, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317. (Pubitemid 47080336)
36. Cellot S, Krosl J, Chagraoui J, Meloche S, Humphries RK, Sauvageau G. Sustained in vitro trigger of self-renewal divisions in Hoxb4hiPbx1(10) hematopoietic stem cells. Exp Hematol 2007;35(5):802-816.
37. Satoh Y, Matsumura I, Tanaka H, Ezoe S, Sugahara H, Mizuki M, Shibayama H, Ishiko E, Ishiko J, Nakajima K, Kanakura Y. Roles for c-Myc in Self-renewal of Hematopoietic Stem Cells. J Biol Chem 2004;279(24):24986-24993. (Pubitemid 38756746)